Progression-free survival of patients with follicular lymphoma in some selected studies that included a substantial proportion of patients with favorable characteristics.
| Reference . | Therapeutic intervention . | Median time to progression, mo . |
|---|---|---|
| Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; 131I, iodine-131 | ||
| 72,73 | Watch and wait | 24 to 32 (time to new treatment) |
| 51,77,53 | 4 weekly rituximab infusions | 18 to 24 |
| 77,55,56 | 4 weekly rituximab infusions followed by maintenance | 32 to 36 |
| 64 | 131I-tositumomab alone | 73 |
| 65 | CHOP followed by 131I-tositumomab | > 60 |
| 78 | Rituximab combined with CHOP | 82 |
| Reference . | Therapeutic intervention . | Median time to progression, mo . |
|---|---|---|
| Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; 131I, iodine-131 | ||
| 72,73 | Watch and wait | 24 to 32 (time to new treatment) |
| 51,77,53 | 4 weekly rituximab infusions | 18 to 24 |
| 77,55,56 | 4 weekly rituximab infusions followed by maintenance | 32 to 36 |
| 64 | 131I-tositumomab alone | 73 |
| 65 | CHOP followed by 131I-tositumomab | > 60 |
| 78 | Rituximab combined with CHOP | 82 |